IPO · 17 August 2026Molbio DiagnosticsPoint-of-care molecular diagnostics platformmolbiodiagnostics.com ↗
Molbio Diagnostics lists at 21% premium on exchanges
By Abha Lohia · Editor ·
Molbio Diagnostics: revenue and funding and every story →
ipo
- Molbio Diagnostics makes point-of-care molecular diagnostic systems for multiple diseases
- Its Rs 939.7 crore IPO listed at Rs 980, a 21.44% premium over the issue price of Rs 807
- The IPO was subscribed 70.27 times, and the company's market cap at listing was Rs 11,628 crore
What happened
- Molbio Diagnostics shares listed on NSE and BSE at Rs 980, a 21.44% premium over the IPO price of Rs 807.
- The IPO size was Rs 939.7 crore, comprising a fresh issue of Rs 200 crore and an offer for sale of Rs 739.7 crore.
- The IPO price band was Rs 768-807 per share, with a lot size of 18 shares and a retail minimum investment of Rs 14,526.
- The IPO was subscribed 70.27 times.
- At listing, the company's market capitalisation was Rs 11,628 crore ($1.22 billion).
- By 10:51 AM on listing day, the share price had risen to Rs 1008.40.
- Before listing, the grey market premium was around Rs 120, indicating an expected price of about Rs 927.
Why it matters
- The strong listing reflects high investor demand for diagnostics companies in India.
- Molbio's Truenat platform gained prominence during the COVID-19 pandemic for its portable testing capability.
- Bill Gates has publicly praised Molbio's role in increasing diagnostic tests and affordability in India.
The business
- Molbio Diagnostics is known for its Truenat platform, a point-of-care molecular diagnostics system for multiple diseases.
- The company places diagnostic devices at healthcare facilities and earns recurring revenue from test kit sales.
- As per IPO documents, the Truenat platform had 30 diseases and 42 assays commercialised.
- Its wholly owned subsidiary Bigtec Labs handles R&D for diagnostic platforms at point-of-care settings.
- The company has a global footprint with installations in Asia/Oceania, Africa/Middle East, Europe/Central Asia, and the Americas.
- Molbio's technology has touched 40+ million lives across 90+ countries (the website also mentions 80+ countries).
- Molbio's EDGE is a global accelerator programme for point-of-need diagnostic technologies.
The founders
- Dr Chandrasekhar Bhaskaran Nair is the founder of Molbio Diagnostics.
- His LinkedIn profile is available at the provided link.
In numbers
Rs 939.7 croreIPO size · 2026
Rs 200 croreFresh issue · 2026
Rs 739.7 croreOffer for sale · 2026
Rs 768-807 per shareIPO price band · 2026
18 sharesLot size · 2026
Rs 14,526Retail minimum investment · 2026
70.27 timesIPO subscription · 2026
Rs 980Listing price · 2026
21.44%Listing premium · 2026
Rs 11,628 crore ($1.22 billion)Market cap at listing · 2026
Rs 1008.40Share price at 10:51 AM on listing day · 2026
~Rs 120Grey market premium · 2026
~Rs 1,455 croreRevenue FY26 · 2026
~Rs 164 croreProfit after tax FY26 · 2026
Rs 139 croreProfit after tax FY25 · 2025
30Diseases on Truenat platform · 2026
42Assays commercialised · 2026
40+ millionLives touched · 2026
90+Countries present · 2026
Words to know
- IPO
- Initial Public Offering, when a company sells shares to the public for the first time.
- Offer for sale
- Existing shareholders sell their shares to the public; the company does not receive any money from this sale.
- Grey market premium
- The price at which IPO shares are traded informally before listing, indicating expected listing price.
- Point-of-care diagnostics
- Medical tests performed at or near the site of patient care, rather than in a central lab.
The numbers around it
Molbio Diagnostics has 1 funding rounds in StopDown's archive.
| When | Round | Amount | Led by |
|---|---|---|---|
| 7 August 2026 | Pre-IPO anchor round | ₹281.5 Cr | Undefined |
Healthcare & Life Sciences in August 2026: 10 rounds with a disclosed amount, $139 million in all; the biggest was Biodeal Pharmaceuticals (₹385 crore). Every sector this year →
Terms in this story
- IPO: An IPO, or initial public offering, is the first time a company sells its shares to the public and lists on a stock exchange. In India SEBI supervises it and the shares trade on the NSE and BSE. A retail investor can bid up to ₹2 lakh, and the issue stays open for three working days.
- IPO subscription: IPO subscription is the number of times investors bid for the shares on offer. A subscription of 50 times, written 50x, means bids were worth fifty times the shares available in that portion. It shows demand, not the quality of the company or the price after listing.
- Market cap vs valuation: Market capitalisation is what a stock market says a listed company is worth right now: share price times shares outstanding. Valuation is the broader word for any estimate of a company's worth, and for a private startup it usually means the price set in its latest funding round.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
Everything on Molbio Diagnostics → · All startup news on 17 August 2026 →
Is this Molbio Diagnostics? Get your “Featured on StopDown” badge →